The Obstructive Sleep Apnea (OSA) is a chronic disease that afflicts approximately 100 million people, however, nearly 80%of people with this condition remain undiagnosed. Sleep Apnea has serious medical consequences but it is also economically costly. In the USA alone the estimated economic cost of undiagnosed OSA is $149.6 billion. The diagnosis of OSA is typically made after a polysomnography (PSG), an expensive test that requires an overnight stay in a sleep laboratory wired to up to 15 different devices. Today the use of Home Sleep Tests are increasing due to are less intrusive and cheaper, however, they are subject to patient error in attaching the sensors, require previous training, are cumbersome and are not appropriate for children. Tarsio Medics is a technological company that has been working during more than 10 years together with the Pneumology unit of the Hospital Trias i Pujol to develop SleepWise, an innovative system for the exploration and diagnosis of OSA based on image processing. Our patented SleepWise system is non-intrusive, low cost, does not require training. It provides automatic analysis for sleep professionals, is more reliable because it can infer sleep/awake periods and is more versatile as it can also detect other nocturnal movements such as restless legs, parasomnias and epilepsy. We plan to monetize SleepWise offering a complete end-to-end service to doctors, hospitals and health insurance companies. The market potential is large: the global sleep apnea diagnostic system market is €341.7 €205.06 of them related with Home Sleep Tests. Currently we have a beta version of the SleepWise. Now we are applying to the SME Instrument Phase 1 to carry out a Feasibility Study to assess operational, technological and economic viability as well as to elaborate a Business Plan to define the business growth, sustainability, exploitation strategies and tactics to follow paving the way to a global market.
